Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,597 across all filing types
Latest filing 2016-01-03 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
关于公司及全资子公司新宁制药、海力制药获得《药品GMP证书》的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Guangdong Taicheng Pharmaceutical Co., Ltd. regarding the receipt of new GMP (Good Manufacturing Practice) certificates for the company and its subsidiaries. It includes details about the certificates, their scope, and validity periods. The document is short (1270 characters) and serves as an official notification rather than a detailed report or financial statement. It does not contain financial data, management discussion, or regulatory certifications. It is not an annual or interim report, nor a call transcript or earnings release. The content fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about compliance and certification, which does not fit into more specific categories.
2016-01-03 Chinese
国信证券股份有限公司关于公司定期现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "定期现场检查报告" which translates to "Periodic On-site Inspection Report" by the sponsor Guosen Securities Co., Ltd. for Guangdong Taicheng Pharmaceutical Co., Ltd. The content includes detailed findings on corporate governance, internal controls, information disclosure, use of raised funds, performance, shareholder commitments, and other important matters. It is a comprehensive report on the company's compliance and operational status during a specific inspection period (January 1, 2015 to December 22, 2015). The document is not an annual or quarterly financial report, nor is it an announcement or a certification. It is a standalone audit or inspection report related to regulatory compliance and internal controls, fitting the category of Audit Report / Information (AR). The length (5790 characters) and detailed content support this classification with high confidence. FY 2015
2015-12-30 Chinese
关于收购台山市新宁制药有限公司完成工商变更的公告
Capital/Financing Update Classification · 95% confidence The document is a company announcement regarding the completion of a business acquisition and related industrial and commercial registration changes. It details the acquisition of Tai Shan Xin Ning Pharmaceutical Co., Ltd. by Guangdong Taicheng Pharmaceutical Co., Ltd., including approval dates, registration information, and business scope. The document is short (1215 characters) and does not contain financial statements or detailed financial performance data. It is not a full annual or interim report, nor an earnings release. It is not a regulatory certification or officer attestation. The content fits best with a Capital/Financing Update (CAP) as it relates to acquisition and ownership changes, which are financing/capital structure related activities. Therefore, the appropriate classification is CAP with high confidence.
2015-12-30 Chinese
关于全资子公司获得药品临床试验批件的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from Guangdong Taicheng Pharmaceutical Co., Ltd. regarding its wholly-owned subsidiary obtaining clinical trial approval certificates for certain pharmaceutical products. It includes a risk warning and a commitment to disclose further information as required. The document is brief (718 characters) and does not contain financial data, financial statements, or detailed report content. It is an official announcement about a regulatory approval event, not a financial report or management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2015-12-29 Chinese
关于归还用于暂时补充流动资金的闲置募集资金的公告
Capital/Financing Update Classification · 95% confidence The document is a short announcement from Guangdong Taicheng Pharmaceutical Co., Ltd. regarding the return of temporarily used idle raised funds to supplement working capital. It mentions the board meeting approval and the completion of the return of funds. The document length is only 614 characters, indicating it is a brief announcement rather than a detailed financial report. There is no financial data or detailed analysis present. This fits the category of a Capital/Financing Update (CAP) as it relates to the use and return of raised capital funds.
2015-12-29 Chinese
关于第三届董事会第二次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the second meeting of the third board of directors of Guangdong Taicheng Pharmaceutical Co., Ltd. It details the board meeting date, attendance, the approval of a supplemental agreement related to a share purchase agreement, and voting results. There is no financial data or comprehensive report content, only a formal announcement of board decisions. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2015-12-28 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.